ASPIrin in Reducing Events in Dialysis ( ASPIRED )

• Status: Recruiting
• Trial end date: 2026-07-01
• Target enrollment: 0
• Participant gender: All

Summary

People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Provincial People's Hospital
• Collaborator: George Clinical Pty Ltd
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Adult patients who are entered into the Chinese PD and HD dialysis registry

• Expected requirement for ongoing maintenance dialysis

• Willing and able to provide informed consent

Exclusion Criteria:

• Requirement of antiplatelet agent or oral anticoagulation, in the view of the treating physician

• Contraindication to aspirin

• Dialysis requirement due to acute kidney injure I with the expectation of kidney function recovery

• History of haemorrhagic stroke or intracranial bleed within the past 12 months

• Coagulopathy from any cause